NASDAQ:EDIT (Editas Medicine)

About EDIT

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
  • Should you invest £1,000 in Editas Medicine right now?

    When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

    Mark and his analyst team just revealed what they believe are the 6 best stocks for investors to buy right now... and Editas Medicine wasn’t on the list. Right now, they think there are 6 stocks that are better buys!

    See the 6 stocks